$AQST Aquestive Therapeutics ($0.90) The Company is developing orally administered products to deliver molecules, providing alternatives to care therapies. It is engaged in advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. The Company's CNS portfolio, which is focused on epilepsy.
Leave a Reply